2056030-06-7

Basic information

• Product Name: N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea p-toluenesulfonate
• CAS NO: 2056030-06-7
• Molecular Weight: 637.03
• Mol File: 2056030-06-7.mol
• Article Data: 33

Chemical Properties

• CAS DataBase Reference: N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea p-toluenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea p-toluenesulfonate(2056030-06-7)
• EPA Substance Registry System: N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea p-toluenesulfonate(2056030-06-7)

Safety Data

• Hazardous Substances Data: 2056030-06-7(Hazardous Substances Data)

Usage

Description

N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea p-toluenesulfonate, also known as Sorafenib Hemitosylate, is a pharmaceutical compound with a complex chemical structure. It is a drug that has been developed for the treatment of human hepatocellular carcinoma (HCC), a type of liver cancer.

Uses

Used in Oncology:
Sorafenib Hemitosylate is used as an anticancer agent for the treatment of hepatocellular carcinoma (HCC). It is designed to target multiple signaling pathways involved in tumor growth and angiogenesis, thereby inhibiting the progression of the disease. However, its effectiveness in clinical use is limited, indicating the need for further research and development to improve its therapeutic potential.

Upstream product

• 327-78-6 4-chloro-3-(trifluoromethyl)phenyl isocyanate 
• 104-15-4 toluene-4-sulfonic acid 
• 284461-73-0 sorafenib 
• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 
• 50528-73-9 4-benzyloxy-phenyl isocyanate 
• 6373-46-2 p-benzyloxyaniline 
• 1145-76-2 benzyl 4-nitrophenyl ether 
• 100-02-7 4-nitro-phenol 
• 1152131-62-8 1-(4-benzyloxy-phenyl)-3-(4-chloro-3-trifluoromethyl-phenyl)-urea 
• 6192-52-5 p-toluenesulfonic acid monohydrate 
• 123-30-8 4-amino-phenol 
• 62150-45-2 4-bromo-2-cyanopyridine 

Relevant articles and documents

Impurity Free and Scalable Process of Sorafenib Tosyalte: Hepatocellular Carcinoma

An efficient, impurities free and scalable process of hepatocellular carcinoma and renal cell carcinoma of sorafenib tosylate with good quality and higher yield.

Sorafenib hemicamsylate and processes for preparation thereof

The present invention relates to: novel sorafenib hemi camsylate salt for treating cancer (chemical formula III); a novel crystalline form thereof; and a method for manufacturing the same. More specifically, the present invention relates to: hemi camsylate salt having high stability, solubility, and purity; a crystalline form thereof; and a method for manufacturing the same. The problem to be solved by the present invention is to provide novel sorafenib salt which is easy to make various preparations, and the method for manufacturing novel salt.COPYRIGHT KIPO 2020

PROCESS FOR THE PREPARATION OF SORAFENIB TOSYLATE POLYMORPH III

The present invention relates to a process for the preparation of sorafenib tosylate form III from sorafenib base through sorafenib tosylate methanol solvate. The present invention relates to an improved process for the preparation of Sorafenib tosylate form III with high purity and high yield. The present process controls the genotoxic impurities content in final API.